BRCA2 and lung cancer: Later, it was shown that both cisplatin (IC50: approximatively 10 nM vs. 10 μM) and PARPi (Olaparib—IC50: approximatively 0.1 μM vs. 10 μM and niraparib) were more active in ERCC1-deficient lung cancer cells (A549) as compared to their ERCC1-expressing controls, although the difference was lower than that between BRCA2-positive (IC50: 1 μM) and BRCA2-negative cells (IC50: approximately 20 nM) [21].